Delcath Q3 Revenue Jumps 71% to $35.1M, 2026 Guidance Raised to $115M-$117M
DCTH has more than doubled off its 52-week low of $8.12.
Summary
Delcath reported Q3 revenue of $35.1 million (up 71% year over year) and net income of $7.0 million, then raised 2026 revenue guidance to $115 million-$117 million. Cash of $104.3 million and no debt mean the growth is self-funded.
Key Events · Earnings and Guidance · DCTH
-
Q3 Revenue Up 71% to $35.1M
Total revenue of $35.1 million versus $20.6 million in Q3 2025, with HEPZATO KIT at $32.7 million and CHEMOSAT at $2.4 million.
-
Net Income $7.0M, EBITDA $11.5M
Net income of $7.0 million versus $0.8 million a year ago; non-GAAP adjusted EBITDA of $11.5 million versus $5.3 million.
-
2026 Guidance Raised to $115M-$117M
Full-year revenue outlook lifted from the prior $104 million-$108 million range, reflecting at least 41% HEPZATO KIT volume growth over 2025.
-
Cash $104.3M, No Debt
Cash and investments of $104.3 million as of September 30, 2026, with $8.2 million of cash provided by operations in the quarter.
Analysis · DCTH · Industrial Applications And Services
The raised guidance is the number that matters for whether the stock holds its 52-week high. Q3 revenue of $35.1 million rose 71% from $20.6 million a year ago, and net income of $7.0 million dwarfed last year's $0.8 million. Management lifted full-year 2026 revenue guidance to $115 million-$117 million from the prior $104 million-$108 million range, implying at least 41% HEPZATO volume growth. With $104.3 million in cash and no debt, the company is funding its own expansion and the DELUMA breast-cancer trial without dilution.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCTH was trading at $16.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $8.12 to $17.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.